The integration of naturalized players into the Chinese national team marked a significant milestone in the nation’s football history. Initially, players like Exon, Alan, and Fernando were seen as key ...

Dyne is eyeing an accelerated approval filing for DYNE-251 in early 2026 that would pit the asset against Sarepta’s Exondys ...

The discovery could pave the way for a groundbreaking RNA-based multi-cancer treatment. Alternative RNA splicing functions ...

In a surprising turn of events, football player Exon has chosen to leave behind the traditional football scene to join a beach football league team after parting ways with Chengdu Rongcheng. This ...

Scientists reveal how cancer cells manipulate RNA splicing, increasing tumor growth. A new study introduces antisense ...

Researchers have discovered that cancer cells suppress 'poison exons' -- genetic elements that act as an off switch for protein production -- in a key gene called TRA2 , promoting tumor growth. By ...

A study reveals how cancer disrupts RNA splicing and presents a potential therapy using antisense oligonucleotides to target ...

In a recent study, scientists not only show how cancer hijacks this tightly regulated splicing and rearranging of RNA but ...

Scientists from The Jackson Laboratory and UConn Health found that cancer cells disrupt poison exons, leading to tumor growth ...

Alternative splicing (AS) of pre-mRNA plays a crucial role in tissue-specific gene regulation, with disease implications due to splicing defects. Predicting and manipulating AS can therefore uncover ...

B. Riley initiates coverage on ArriVent Biopharma, citing firmonertinib's potential in NSCLC. The analyst sees strong upside with a $37 price target.